BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
250.30
-3.09 (-1.22%)
Jul 11, 2025, 4:00 PM - Market closed
BeOne Medicines Revenue
BeOne Medicines had revenue of $1.12B in the quarter ending March 31, 2025, with 48.64% growth. This brings the company's revenue in the last twelve months to $4.18B, up 51.16% year-over-year. In the year 2024, BeOne Medicines had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.18B
Revenue Growth
+51.16%
P/S Ratio
6.35
Revenue / Employee
$379,624
Employees
11,000
Market Cap
29.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ONC News
- 2 days ago - European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma - Business Wire
- 2 days ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Business Wire
- 16 days ago - BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day - Business Wire
- 17 days ago - BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® - Business Wire
- 25 days ago - BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium - Seeking Alpha
- 4 weeks ago - BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 - Business Wire
- 4 weeks ago - U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications - Business Wire
- 4 weeks ago - BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 - Business Wire